Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
暂无分享,去创建一个
Huy Trinh | Robert Flisiak | Franck Rousseau | M. Manns | M. Buti | P. Marcellin | K. Kaita | R. D. de Man | M. Shiffman | K. Borroto-Esoda | E. Gane | P. Buggisch | R. Flisiak | Samuel S. Lee | J. Heathcote | F. Rousseau | E. Mondou | Maria Buti | Edward Gane | E. Heathcote | S. Gurel | E. Heathcote | Z. Krastev | I. Kotzev | K. Tchernev | Michael Manns | Patrick Marcellin | Peter Buggisch | Jeff Sorbel | Elsa Mondou | E. Jenny Heathcote | Robert A. De Man | Zahary Krastev | George Germanidis | Samuel S. Lee | Kelly Kaita | Iskren Kotzev | Konstantin Tchernev | Frank Weilert | Oya Ovunc Kurdas | Mitchell L. Shiffman | Selim Gurel | Andrea Snow–Lampart | Katyna Borroto–Esoda | Jane Anderson | H. Trinh | Andrea Snow–Lampart | O. O. Kurdaş | F. Weilert | Jane Anderson | J. Sorbel | Ichael P. Manns | G. Germanidis | R. Man | Jane Anderson | Ahary Krastev | YA Ovunc Kurdas | N. S. –. Lampart | K. B. –. Esoda | Eff Sorbel | Mitchell L. Shiffman | Mitchell L. Shiffman | Samuel S. Lee | Robert A. De Man | Andrea Snow‐Lampart | Michael Manns | Jenny Heathcote | R. A. D. Man | Ahary Krastev | YA Ovunc Kurdas | N. S. –. Lampart | K. B. –. Esoda | Eff Sorbel
[1] G. Fattovich,et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.
[2] Huy Trinh,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.
[3] F. Tacke,et al. Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.
[4] T. Berg,et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. , 2010, Gastroenterology.
[5] P. Loehrer,et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .
[6] T. Asselah,et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. , 2009, Journal of hepatology.
[7] G. Fattovich,et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years , 2007, Gut.
[8] M. Yuen,et al. Natural history of chronic hepatitis B virus infection , 2000, Journal of gastroenterology and hepatology.
[9] D. But,et al. Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy: 7-year experience , 2005 .
[10] T. Asselah,et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.
[11] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[12] Chien-Jen Chen,et al. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma , 2007 .
[13] Richard D Moore,et al. Renal function with use of a tenofovir-containing initial antiretroviral regimen , 2009, AIDS.
[14] K. Simon,et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.
[15] P. Marcellin,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.
[16] B. McMahon. The natural history of chronic hepatitis B virus infection , 2009, Hepatology.
[17] H. Chae,et al. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV) , 2008, Hepatology international.
[18] Chien-Jen Chen,et al. Risk and predictors of mortality associated with chronic hepatitis B infection. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[19] M. Ghany,et al. Antiviral resistance and hepatitis B therapy , 2009, Hepatology.
[20] Michael D. Miller,et al. Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus , 2006, Antimicrobial Agents and Chemotherapy.
[21] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[22] H. Janssen,et al. Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.
[23] Olga Angelopoulou,et al. Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels , 2007, Antiviral therapy.
[24] Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998 .
[25] M. Buti,et al. TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS , 2008 .
[26] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[27] Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998 .
[28] C. Chu,et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.
[29] J. Gallant,et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients , 2008, AIDS.
[30] A. Lok,et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. , 2008, Journal of hepatology.
[31] M. Yuen,et al. The relationship between HBV‐DNA levels and cirrhosis‐related complications in Chinese with chronic hepatitis B , 2005, Journal of viral hepatitis.
[32] P. Marcellin,et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.
[33] T. Berg,et al. Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.